Home › Corticobasal Degeneration › NCT07000851
Imaging Studies in Corticobasal Syndrome
Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age 18 years or older * Meet possible or probable CBS criteria Exclusion Criteria: * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
About the study
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
What is being tested
- C-11 ER176 Radiotracer (diagnostic test)
- C-11 PiB (diagnostic test)
- AV1451 Tau (diagnostic test)
Sponsor: Jennifer Whitwell · Participants: 80 · Started: Jun 25, 2025
Contact the study team
- Megan J Meyer, M.B.A. · Phone: 507-293-1164
- Sarah M Boland, CCRP · Phone: 507284-3863
Official record on ClinicalTrials.gov — NCT07000851
Locations in the U.S.
| Minnesota | Mayo Clinic, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.